BACKGROUND: Cancer-related cognitive decline (CRCD) is an important clinical problem, but limited research exists on assessment of cognitive function in patients with lymphoma. METHODS: The overall objective of this nationwide, prospective, observational study conducted in the National Cancer Institute Community Clinical Oncology Research Program (NCORP) was to assess changes in memory, attention, and executive function in patients with lymphoma from pre- (A1) to postchemotherapy (A2) and to 6 months postchemotherapy (A3). Individuals without cancer served as noncancer controls, paired to patients by age and sex, and assessed at the same time-equivalent points. Longitudinal linear mixed models (LMM) including A1, A2, and A3 and adjusting for age, education, race, sex, cognitive reserve score, baseline anxiety, and depressive symptoms were fit. We assessed changes in patients compared with control participants without cancer and assessed differences in cognitive function in those patients with Hodgkin vs non-Hodgkin disease and by disease subtype. All statistical tests were 2-sided. RESULTS: Patients with lymphoma (n = 248) and participants without cancer serving as controls (n = 212) were recruited from 19 NCORP sites. From pre- to postchemotherapy and from prechemotherapy to 6 months follow-up, patients reported more cognitive problems over time compared with controls (Functional Assessment of Cancer-Therapy-Cognitive Function [FACT-Cog] perceived cognitive impairment effect size (ES) = 0.83 and 0.84 for A1 to A2 and A1 to A3, respectively; P < .001; single-item cognitive symptoms ES range = 0.55 to 0.70 inclusive of A1 to A2 and A1 to A3; P < .001); the complaints were more pronounced in women with lymphoma compared with men with lymphoma (FACT-Cog Perceived Cognitive Impairment (PCI) score group-by-time-by-sex interaction, P = .007). Patients with lymphoma also performed statistically significantly less well on tests of verbal memory and delayed recall, attention and executive function, and telephone-based category fluency. CONCLUSION: Patients with lymphoma experience worse patient-reported and objectively assessed cognitive function from prechemotherapy to 6-month follow-up compared with age- and sex-paired controls without cancer assessed at similar time intervals.
BACKGROUND: Cancer-related cognitive decline (CRCD) is an important clinical problem, but limited research exists on assessment of cognitive function in patients with lymphoma. METHODS: The overall objective of this nationwide, prospective, observational study conducted in the National Cancer Institute Community Clinical Oncology Research Program (NCORP) was to assess changes in memory, attention, and executive function in patients with lymphoma from pre- (A1) to postchemotherapy (A2) and to 6 months postchemotherapy (A3). Individuals without cancer served as noncancer controls, paired to patients by age and sex, and assessed at the same time-equivalent points. Longitudinal linear mixed models (LMM) including A1, A2, and A3 and adjusting for age, education, race, sex, cognitive reserve score, baseline anxiety, and depressive symptoms were fit. We assessed changes in patients compared with control participants without cancer and assessed differences in cognitive function in those patients with Hodgkin vs non-Hodgkin disease and by disease subtype. All statistical tests were 2-sided. RESULTS: Patients with lymphoma (n = 248) and participants without cancer serving as controls (n = 212) were recruited from 19 NCORP sites. From pre- to postchemotherapy and from prechemotherapy to 6 months follow-up, patients reported more cognitive problems over time compared with controls (Functional Assessment of Cancer-Therapy-Cognitive Function [FACT-Cog] perceived cognitive impairment effect size (ES) = 0.83 and 0.84 for A1 to A2 and A1 to A3, respectively; P < .001; single-item cognitive symptoms ES range = 0.55 to 0.70 inclusive of A1 to A2 and A1 to A3; P < .001); the complaints were more pronounced in women with lymphoma compared with men with lymphoma (FACT-Cog Perceived Cognitive Impairment (PCI) score group-by-time-by-sex interaction, P = .007). Patients with lymphoma also performed statistically significantly less well on tests of verbal memory and delayed recall, attention and executive function, and telephone-based category fluency. CONCLUSION: Patients with lymphoma experience worse patient-reported and objectively assessed cognitive function from prechemotherapy to 6-month follow-up compared with age- and sex-paired controls without cancer assessed at similar time intervals.
Authors: Michelle C Janelsins; Charles E Heckler; Luke J Peppone; Charles Kamen; Karen M Mustian; Supriya G Mohile; Allison Magnuson; Ian R Kleckner; Joseph J Guido; Kelley L Young; Alison K Conlin; Lora R Weiselberg; Jerry W Mitchell; Christine A Ambrosone; Tim A Ahles; Gary R Morrow Journal: J Clin Oncol Date: 2016-12-28 Impact factor: 44.544
Authors: Philipp Zimmer; Andreas Mierau; Wilhelm Bloch; Heiko K Strüder; Thorben Hülsdünker; Alexander Schenk; Leonie Fiebig; Freek T Baumann; Moritz Hahn; Nina Reinart; Michael Hallek; Thomas Elter Journal: Leuk Lymphoma Date: 2014-06-05
Authors: Janette L Vardy; Haryana M Dhillon; Gregory R Pond; Sean B Rourke; Tsegaye Bekele; Corrinne Renton; Anna Dodd; Haibo Zhang; Philip Beale; Stephen Clarke; Ian F Tannock Journal: J Clin Oncol Date: 2015-11-02 Impact factor: 44.544
Authors: Jeanne S Mandelblatt; Robert A Stern; Gheorghe Luta; Meghan McGuckin; Jonathan D Clapp; Arti Hurria; Paul B Jacobsen; Leigh Anne Faul; Claudine Isaacs; Neelima Denduluri; Brandon Gavett; Tiffany A Traina; Patricia Johnson; Rebecca A Silliman; R Scott Turner; Darlene Howard; John W Van Meter; Andrew Saykin; Tim Ahles Journal: J Clin Oncol Date: 2014-05-19 Impact factor: 44.544
Authors: Anna Barata; Aasha I Hoogland; Anuhya Kommalapati; Jennifer Logue; Taylor Welniak; Kelly A Hyland; Sarah L Eisel; Brent J Small; Reena V Jayani; Margaret Booth-Jones; Laura B Oswald; Brian D Gonzalez; Kedar S Kirtane; Michael D Jain; Sepideh Mokhtari; Julio C Chavez; Aleksandr Lazaryan; Bijal D Shah; Frederick L Locke; Heather S L Jim Journal: Transplant Cell Ther Date: 2022-05-14
Authors: Haryana M Dhillon; Karla Gough; Priscilla Gates; Meinir Krishnasamy; Carlene Wilson; Eliza A Hawkes; Vincent Doré; Yuliya Perchyonok; Christopher C Rowe; Adam K Walker; Janette L Vardy; Michiel B de Ruiter; Tania Cushion Journal: Support Care Cancer Date: 2022-06-14 Impact factor: 3.359